mProX™ Human PIK3CA Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The applications of PIK3CA include its role as a targetable driver alteration in histiocytic neoplasms, such as Langerhans cell histiocytosis (LCH). Activating mutations in PIK3CA have been shown to drive histiocytic neoplasms in vivo, and targeted inhibition of PI3K using the inhibitor alpelisib has demonstrated successful treatment of PIK3CA-mutated LCH. In endometrial cancer, the PIK3CA-PIK3R1-PTEN pathway is implicated in the pathogenesis of the disease, and alterations in ErbB receptors, including ErbB-2, are observed in aggressive histologic subtypes, suggesting a potential role for ErbB-targeted therapies in these subgroups. In cervical cancer, cervical cancers carrying PIK3CA helical domain mutations exhibit redox adaptation and resistance to therapy. SGK3, activated upon oxidative stress, promotes cell growth and drug resistance by stabilizing and activating the antioxidant enzyme catalase. In anal cancer, preclinical models have been developed to assess anal cancer treatments, including combined-modality therapy (CMT) with radiation and chemotherapy. These models have shown increased survival with CMT treatment and the potential efficacy of LY3023414, a drug effective in cancer prevention, in reducing tumor size. Overall, these studies highlight the diverse applications of PIK3CA in various cancer types and the potential for targeted therapies.